NCMA-CMA Certified Medical Assistant dumps with real questions made up good pass marks

We are prompted that an essential issue in the IT business is that there is the unavailability of important NCMA-CMA cheat sheet. Our test prep Practice Questions gives every one of you that you should take a certification test. Our Medical NCMA-CMA Practice Questions will offer you actual test questions with substantial responses that reflect the authentic test. We at killexams.com are made game plans to draw in you to finish your NCMA-CMA test with high scores.

Exam Code: NCMA-CMA Practice test 2022 by Killexams.com team
Certified Medical Assistant
Medical Certified test
Killexams : Medical Certified test - BingNews https://killexams.com/pass4sure/exam-detail/NCMA-CMA Search results Killexams : Medical Certified test - BingNews https://killexams.com/pass4sure/exam-detail/NCMA-CMA https://killexams.com/exam_list/Medical Killexams : Todos Medical Initiates Validation Plan for PCR-based MonkeyPox Test at CLIA/CAP Clinical Testing Laboratory Provista Diagnostics

Todos Medical Ltd.

§  Lesion swab (standard of care) and saliva-based demo collection planned

§  Peer-reviewed publication demonstrating saliva testing sensitivity opens door for asymptomatic testing


New York, NY, and Tel Aviv, ISRAEL, Aug. 03, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today announced that its CLIA/CAP-certified laboratory Provista Diagnostics has initiated a validation plan for PCR-based MonkeyPox testing. Under the plan, the Company is validating multiple PCR assays for MonkeyPox and will launch the most sensitive for lesion-based and saliva-based demo collections. While lesion-based testing is the current standard of care according to CDC guidelines, saliva-based demo collection is currently undergoing intense research that could open up the potential for testing of asymptomatic or very early-stage patients at high risk of severe disease (such as immunocompromised patients) that could result in earlier diagnosis and early intervention with therapeutic drugs such as Tecovirimat (TPOXX). TPOXX is an investigational drug candidate, and currently only available under an expanded access Investigational New Drug (EA-IND) protocol. The MonkeyPox tests are being developed as Laboratory Developed Tests (LDTs). A latest peer-reviewed article describing strong correlation of the sensitivity of lesion and saliva-based PCR testing was recently published in the journal Eurosurveillance: https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2022.27.28.2200503

“The significant investment we made to automate PCR testing at Provista to maximize COVID testing capacity can now be partially redeployed towards MonkeyPox as we prepare to help the nation scale-up MonkeyPox testing capacity to meet the emerging public health crisis,” said Gerald E. Commissiong, President & CEO of Todos Medical.

About Todos Medical Ltd.
Founded in Rehovot, Israel with offices in New York City, Todos Medical Ltd. (OTCQB: TOMDF) engineers life-saving diagnostic solutions for the early detection of a variety of cancers. The Company's state-of-the-art and patented Todos Biochemical Infrared Analyses (TBIA) is a proprietary cancer-screening technology using peripheral blood analysis that examines cancer's influence on the immune system, looking for biochemical changes in blood mononuclear cells and plasma. Todos’ two internally developed cancer-screening tests, TMB-1 and TMB-2 have received a CE mark in Europe. Todos recently acquired U.S.-based medical diagnostics company Provista Diagnostics, Inc. to gain rights to its Alpharetta, Georgia-based CLIA/CAP certified lab currently performing PCR COVID testing, Long COVID Panel, and Provista's proprietary commercial-stage Videssa® breast cancer blood test.

Todos is also developing blood tests for the early detection of neurodegenerative disorders, such as Alzheimer's disease. The Lymphocyte Proliferation Test (LymPro Test™) is a diagnostic blood test that determines the ability of peripheral blood lymphocytes (PBLs) and monocytes to withstand an exogenous mitogenic stimulation that induces them to enter the cell cycle. It is believed that certain diseases, most notably Alzheimer's disease, are the result of compromised cellular machinery that leads to aberrant cell cycle re-entry by neurons, which then leads to apoptosis. LymPro is unique in the use of peripheral blood lymphocytes as a surrogate for neuronal cell function, suggesting a common relationship between PBLs and neurons in the brain.

Todos formed the Israeli-based majority-owned joint venture 3CL Pharma, Ltd with NLC Pharma in March of 2022 to consolidate all of the intellectual property pursuing the development of diagnostic tests targeting the 3CL protease, as well as 3CL protease inhibitor botanical and pharmaceutical products that target a fundamental reproductive mechanism of coronaviruses. 3CL Pharma, through Todos’ brand, has commercialized the 3CL protease inhibitor immune support dietary supplement Tollovid® in the United States, is developing the dual mechanism 3CL protease inhibitor & anti-cytokine therapeutic drug candidate Tollovir®, while also developing the 3CL protease inhibitor diagnostic TolloTest™.

To purchase Tollovid please visit Amazon or www.MyTollovid.com. For more information, please visit https://www.todosmedical.com/.

Forward-looking Statements
Certain statements contained in this press release may constitute forward-looking statements. For example, forward-looking statements are used when discussing our expected clinical development programs and clinical trials. These forward-looking statements are based only on current expectations of management, and are subject to significant risks and uncertainties that could cause real results to differ materially from those described in the forward-looking statements, including the risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval or patent protection for product candidates; competition from other biotechnology companies; and our ability to obtain additional funding required to conduct our research, development and commercialization activities. In addition, the following factors, among others, could cause real results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; delays or obstacles in launching our clinical trials; changes in legislation; inability to timely develop and introduce new technologies, products and applications; lack of validation of our technology as we progress further and lack of acceptance of our methods by the scientific community; inability to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties that may develop with our process; greater cost of final product than anticipated; loss of market share and pressure on pricing resulting from the competition; and laboratory results that do not translate to equally good results in real settings, all of which could cause the real results or performance to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, Todos Medical does not undertake any obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertainties affecting Todos Medical, please refer to its reports filed from time to time with the U.S. Securities and Exchange Commission.

Todos Corporate Contact:
Daniel Hirsch
CFO
Todos Medical
917-983-4229 x 104
Dan.h@todosmedical.com

Tue, 02 Aug 2022 23:52:00 -0500 en-US text/html https://finance.yahoo.com/news/todos-medical-initiates-validation-plan-115200000.html
Killexams : North American Diagnostics latest to recall COVID-19 tests, gets Class I label from FDA

North American Diagnostics has recalled over 122,000 oral rapid COVID-19 antigen test kits because the products were distributed to customers in the U.S. without authorization, clearance or approval from the Food and Drug Administration.

The company is the latest medtech firm to recall COVID-19 tests due to unlawful distribution in the U.S., joining Roche partner SD Biosensor, Acon Laboratories and SML Distribution.

The FDA labeled the recall a Class I event. The agency wrote that the products have the possibility of false positive or negative test results, misinterpretation of results and serious adverse health consequences, including death. According to the FDA’s Monday notice, there have been no reports of injuries or death associated with the recall.

“North American Diagnostics did not provide the FDA with adequate validation data to show that the test's performance is accurate,” the agency wrote. 

The product is known as the Oral Rapid SARS-CoV-2 Rapid Antigen Test Kit, and may also be called Oral Rapid Test or Oral Rapid Antigen Test, Lateral Flow COVID 19 Rapid Antigen Test, Skippack Medical Lab rapid antigen tests, Skippack COVID-19 Antigen Home Test, SML LDT Kits and other SML brand kits.

The recall affects 122,175 devices distributed between March 1, 2021, and Feb. 15, 2022.

North American Diagnostics sent an email to customers and distributors on June 15 asking for any existing devices to be quarantined and immediately destroyed.

Tue, 02 Aug 2022 03:16:00 -0500 Ricky Zipp en-US text/html https://www.medtechdive.com/news/north-american-diagnostics-recall-covid-19-tests-fda/628626/
Killexams : Skin Test Accurately IDs Alzheimer's Even in the Presence of Comorbid Pathologies

A minimally invasive skin test can accurately diagnose Alzheimer's Disease (AD) with high sensitivity and specificity, even in the presence of comorbid pathologies, new research suggests.

Dr Daniel Alkon

The test, which measures factors related to synaptic connections in the brain, could be added to other testing to "tremendously enhance the certainty of making [an AD] diagnosis," Daniel Alkon, MD, chief scientific advisor at SYNAPS Dx, the company behind the test, told Medscape Medical News.

The findings were presented at the Alzheimer's Association International Conference (AAIC) 2022.

Better Specificity Needed

Clinical trials testing potential AD therapies typically include patients without a definitive diagnosis for AD dementia. That is because diagnoses are often uncertain, particularly during the first 4-5 years of the disease.

Several tests to detect AD signs have been developed. These include MRI and PET scan tests for amyloid plaque, cerebrospinal fluid, and plasma measures of soluble amyloid and tau, and blood levels of tau.

However, none of these tests have been extensively validated at autopsy, said Alkon. Previous studies have shown over 50% of patients do not have AD alone. Instead, they also have other pathologies, such as Parkinson's Disease, frontal lobe dementia, or multi-infarct dementia, Alkon noted.

"It's not enough for a test to discriminate Alzheimer's from a control person who is not demented. It is only valuable if you can discriminate it from other kinds of dementia," Alkon said.

He noted that while beta-amyloid and tau are used as "pathological red flags" to identify AD at autopsy, they are not great at definitively diagnosing the disease because they are not closely correlated with cognitive deficits.

There is an "urgent unmet medical need" for a highly accurate, easily accessible AD biomarker, he said.

Enter the industry certified DISCERN test (SYNAPS Dx) that measures factors related to synaptic connections in the brain, which Alkon said is a better indicator of AD than amyloid or tau. Such factors include synaptic loss, neuronal death, inflammation, amyloid deposition, and hyperphosphorylation of tau protein.

One of the assays in the test is the Morphometric Imaging assay, which was previously shown to closely correlate skin cell abnormalities with dementia and presence of AD pathology in the brains of patients with AD.

"The studies correlate what's happening in the brain of a patient with what's happening elsewhere,” said Alkon. "The inference is [that] the disease has systemic expression; it's not just affecting the brain but affecting the whole system."

New and Unique?

In the current study, researchers obtained a small skin demo through a skin punch biopsy from 74 participants. Of these participants, 26 had AD, which was later confirmed following an autopsy; 21 had non-AD dementia (non-ADD); and 27 did not have dementia and acted as the control group.

The investigators found that AD cell lines formed large aggregates, while non-ADD or control-group cell samples formed smaller and more numerous aggregates. The researchers then counted the number of aggregates and measured the aggregates' average area.

This led them to distinguish patients with AD from those with non-ADD. The probability distributions of the morphometric imaging signals showed clear separation of the measurements for individual patients with AD and for group values for patients with non-ADD.

Based on these results, the sensitivity of the MI assay for diagnosing AD was determined to be 100% (95% CI, 86% - 100%), while the specificity was also 100% (95% CI, 84% - 100%).

Researchers also used samples from patients with dementia who were older than 55 years and who had a blinded autopsy examination. AD specificity held up even in cases with pathologic co-morbidity, including AD with dementias such as Parkinson's disease, Pick's disease, and frontal lobe dementia.

"What's new and unique is we have shown we can measure AD even in patients who have comorbidity; that is, patients who have these other dementias," said Alkon.

Next Steps

Alkon noted this type of research is time-consuming and requires "resources, persistence and determination." A death and confirming autopsy can take place years after a skin test and clinical diagnosis.

The company's main laboratory already analyzes samples of suspected AD cases, but "we are Studying to launch nationally," said Alkon.

"Clinicians should use all available armamentarium measurements they can before making a diagnosis of Alzheimer's Disease, and they should be thorough and cautious," he added.

The company is currently seeking US Food and Drug Administration approval of the skin test and has received breakthrough status.

The test could help rule out other causes of dementia for which there are treatments, such as a thyroid disorder, major depression, and vitamin B12 deficiency, Alkon noted.

He acknowledged that if the test does indicate AD, there are few effective treatments available. "In my opinion, none of the drugs available today actually treat the underlying disease," he said.

However, he noted that could change. Alkon is also president of Synaptogenix, a company developing a therapeutic aimed at enhancing the synaptic growth pathway.

Early Days

Commenting on the study for Medscape Medical News, Rebecca Edelmayer, PhD, senior director of scientific engagement at the Alzheimer's Association, said she is encouraged by this skin puncture test and other research into Alzheimer's diagnostics.

However, she cautioned these tests are at a very early stage. "An important step in moving these tests forward for broader use is to study them in large-scale clinical trials," Edelmayer said.

She noted the DISCERN test analyzes protein kinase C (PKC) signaling markers, which have not yet been validated in large trials to support their use as a diagnostic for AD.

Edelmayer also pointed out this test does not have FDA clearance. "It's important for consumers to be informed about how broad or not these tools have been evaluated," she said.

There is currently no single test that diagnoses AD, she added.

The study was funded by SYNAPS.

Alzheimer's Association International Conference (AAIC) 2022: Abstract 63141. Presented July 31, 2022.

For more Medscape Neurology news, join us on Facebook and Twitter

Wed, 03 Aug 2022 12:00:00 -0500 en text/html https://www.medscape.com/viewarticle/978679
Killexams : 7 Key Considerations When Choosing A Medical Marijuana Doctor

Medical marijuana continues to gain popularity among many individuals with various health conditions. As more states legalize marijuana use, consulting a medical marijuana doctor is a good idea if you want to try it out but want to make sure you're working with a reputable one.

As the medicinal marijuana market is expanding, so does the number of purported doctors specializing in the field. Finding a trustworthy doctor is essential to ensure a positive experience with medical marijuana as a treatment for your ailment. When it's your first try, the options available can be overwhelming, and it can be challenging to find the right one. You might want to check out Medical Marijuana Doctors RX and other similar sources to ensure a good start with your search.  

When researching the numerous medical marijuana doctors in your area, keep the following factors in mind.

  1. Licenses And Certifications

The license and certifications are essential when choosing a medical marijuana physician. It's vital to find out whether your prospective doctor is licensed. It's an important consideration because consuming marijuana without a prescription or with a fraudulent one can lead to legal problems in several states. 

During the selection process, make it a priority to ask about the license beforehand. Look up the license number as a precautionary measure so you'll have peace of mind. Keep in mind that a licensed medical marijuana doctor must also be authorized to issue medical marijuana cards.

A reputable medical marijuana doctor should be able to provide proof of certification as well. Doctors should be certified by accredited institutions. Certification shows that they've completed all required training and passed all mandatory tests.

  1. Years Of Industry Experience

Aside from the licenses and certifications, it'd be best if you also determined how long the doctor has been in the industry to be sure they have the right skills and expertise. Depending on your health condition, it's best to know if a doctor can handle it to ensure the best quality of care with medical marijuana.  

  1. Recommendations From Family Or Friends

If you have family members or friends who use medical marijuana, they may be able to provide suggestions to help you make the right choice. Remember that word of mouth is usually a good start because you get the best options.

  1. Scrutinize Online Reviews And Testimonials  

Finding the right medical marijuana doctor will take time and effort to ensure you choose a reputable one. Before deciding, read online reviews or feedback from previous clients.

It'd be best to read both the positive and negative reviews on their websites and social media pages so you'll have an insight into the quality of the services a particular doctor delivers. Social media profiles are also one way to gauge how a doctor interacts with their patients, which is worth considering if a clinic best suits your needs. 

Don't forget to check the date of the reviews. If the majority of the positive reviews are from years ago, the administration has likely changed, or the service's quality has deteriorated, as evidenced by more latest negative feedback.

  1. Location 

The location is also important when looking for a medical marijuana doctor. If you want convenience, the location is critical.

A doctor in your area or one with multiple locations should be one of your top priorities. When a doctor has multiple clinics, it's obvious that they have more resources and a larger workforce to provide the best service.

  1. Examine The Flow Of The Procedure

Before you make an appointment with the first medical marijuana doctor on your list, make sure you understand how their processes work, as they differ from one doctor to the next.

Most doctors will likely charge various fees for qualification or require you to present specific documents. With this in mind, it's best to check how the procedure works, including the acceptable payments. 

Today, most doctors only accept cash, credit, or debit payments. Payment options will differ from one doctor to the next, so be prepared. The average length of each appointment varies, but it's usually between 30 minutes and an hour.

  1. Express Any Concerns Or Questions

Among the various considerations, you should always ask questions during the selection process. A reputable medical marijuana doctor should have the resources and well-trained staff to address any concerns you may have right away.

Preparing a list of all your concerns and calling the clinics you've shortlisted before visiting is one approach worth considering. Those who stand out should be able to supply you straightforward answers to all of your questions and concerns.

Aside from getting all the information you need from a phone call, don't forget to check their websites. A reputable doctor should have a website that offers an array of information about the services they offer along with highly informative resources on medical marijuana, including the various forms it's available in, such as oil, capsules, liquid, or even edibles

Final Thoughts  

Deciding on the appropriate medical marijuana doctor to work with can be challenging due to the many available options. It's a task that requires careful consideration since it's for your overall health and something you don't want to skimp on. These helpful hints will serve as your guide in assisting you in making the right decision for your health.

Thu, 04 Aug 2022 11:33:00 -0500 en-AU text/html https://thegreenfund.com/7-key-considerations-when-choosing-a-medical-marijuana-doctor
Killexams : Misdiagnosis: Concerns Over Conflicting Medical Test Results No result found, try new keyword!There are growing concerns over conflicting medical test results from private and public medical laboratories in the country.Findings reveal that this has left in its wake, deaths and negative ... Sat, 30 Jul 2022 12:00:00 -0500 en text/html https://www.msn.com/en-xl/africa/other/misdiagnosis-concerns-over-conflicting-medical-test-results/ar-AA109aAd Killexams : CareerStep Launches Training Program to Meet Growing Demand for Medical Lab Assistants

Workforce training pioneer's flexible, skills-focused approach helps working learners earn credentials for in-demand allied health roles

BOSTON, Aug. 2, 2022 /PRNewswire/ -- Penn Foster-Carrus, whose jobtech platform is used by major employers nationwide to identify, recruit, and train workers for middle-skill careers, today announced the launch of a new training program for the fast-growing medical laboratory assistant role. Available through CareerStep, the new course prepares learners to sit for two industry-recognized and employer-preferred certification exams: the American Medical Technologists (AMT) Certified Medical Laboratory Assistant (CMLA) test and the National Healthcare Association (NHA) Certified Phlebotomist Technician (CPT) exam.

Penn Foster (PRNewsfoto/Penn Foster)

The Bureau of Labor Statistics estimates that the demand for clinical lab-related skills will continue to accelerate in the next 8 years, as the volume of laboratory tests increases to meet both population growth and the development of new types of medical diagnostics. Penn Foster-Carrus' portfolio of healthcare training programs already includes in-demand fields like Phlebotomy, Medical Assistant, and Hemodialysis Technician; the addition of the Medical Laboratory Assistant program will enable more working learners to access affordable, job-aligned training programs that help them take the next step in their careers. Thanks to the unique design of the program's externship course, learners who complete and pass the certification exams will be fully certified for the role, with no other additional requirements needed.

"Middle-skill roles like medical lab assistant are critical to the country's labor market, and play a vital role in ensuring quality of care amidst a rapidly changing healthcare landscape," said Misty Frost, CEO of Penn Foster-Carrus. "This is not just about meeting the most immediate talent needs of hospital systems and healthcare providers, but also building a skilled workforce that is better-prepared to navigate a complex and dynamic labor market in the years to come."

Penn Foster and Carrus, which combined in 2021, now provide training in middle-skill fields like allied health, design, and skilled trades for more than 450,000 learners each year.

About Penn Foster
Penn Foster is bridging the gap between education and economic opportunity to build the workforce of tomorrow. We partner with employers to design and deliver digital and blended learning programs that attract, upskill, and retain workers in America's fastest-growing fields and professions. With more than 40,000 graduates each year, Penn Foster helps individuals discover pathways to opportunity through accredited diploma, certificate and degree programs that matter in the world of work. For more information, visit https://www.partners.pennfoster.edu.

About Carrus
Carrus delivers quality, trusted healthcare learning content, continuing education, and certification management to new learners, healthcare professionals, and institutions through an integrated technology platform that provides the most seamless healthcare learning experience possible. In 25+ years, Carrus—through its CareerStep and CareerCert divisions—has trained over 150,000 learners for new careers, partnered with more than 150 colleges and universities nationwide, and educated more than 100,000 healthcare professionals

Cision

View original content to download multimedia:https://www.prnewswire.com/news-releases/careerstep-launches-training-program-to-meet-growing-demand-for-medical-lab-assistants-301597177.html

SOURCE Penn Foster

Tue, 02 Aug 2022 01:00:00 -0500 en-US text/html https://finance.yahoo.com/news/careerstep-launches-training-program-meet-130000292.html
Killexams : Todos Medical Partners with Amerimmune Diagnostics on Long COVID Biomarker Panel

Tel Aviv - ( NewMediaWire ) - July 28, 2022 - Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today announced that its CLIA/CAP certified clinical laboratory Provista Diagnostics has entered into an agreement with Amerimmune Diagnostics, a CLIA/CAP certified laboratory with expertise in immune diagnostics and a leader in the field of clinical immunology and immune assessment of acute and long-COVID.  Amerimmune will provide Provista clinically validated immune panels to assess patients with acute and long-COVID.  Provista will complement the testing by measuring the immune system’s ability to produce neutralizing antibodies to the SARS-CoV-2 virus.  All of the tests that are part of the Long COVID are currently covered by commercial insurance. The Long COVID Panel will provide key insights on inflammatory responses related to immune system cells, whether a patient is immune compromised, and whether a patient produces neutralizing antibodies. When a patient is deemed to be immune compromised, the patient becomes eligible for Evusheld(R) treatment.  If there is evidence of inflammation, then the patients may benefit from various approaches, as deemed clinically appropriate by the treating physician.  Amerimmune has an established nationwide blood demo collection agreement in place with Quest Diagnostics to facilitate access for Long COVID patients interested in getting tested.

“The COVID-19 pandemic has led to a massive population of survivors with immune abnormalities that are clinically presenting as Long COVID,” said Dr. Oral Alpan, Chief Medical Officer of Amerimmune Diagnostics. “Our new Long COVID Panel, which is comprised of our Standard Immunophenotyping Panel, our COVID Phenotyping Assay, and Provista’s total SARS-CoV-2 antibody panel and cPass surrogate viral neutralization test (sVNT or “cPass”), will allow us to provide valuable information for physicians who are looking to monitor the health of patients who have Long COVID and measure whether certain interventions are having an impact on objective biomarkers. Todos has brought to market the 3CL protease inhibitor immune support dietary supplement Tollovid that is beginning to gain traction in the Long COVID community. We believe that monitoring of the immune system’s core functions to the management of Long COVID is necessary in order to identify areas where intervention with therapeutics and/or dietary supplements may play a role in bringing biomarkers back into balance in a way that could result in symptomatic improvements.”

The Long COVID Panel consists of the following markers: lymphocyte subsets; T Cell panel -  monitoring, activation markers, and memory (CD3, CD4, CD8, HLA-DR, CD25, CD57, TCR α/β TCR γ/δ; CD8, CD4 T cell memory);  B cell panel (CD5, CD19, CD20, CD21, B cell surface antibodies, CD27, unswitched memory cells), LAG-3, Caspase-1, ICOS, HLA-DR, CD3, CD4, CD45RA, CD45RO, CD38,  CD28, CD8, CD45, CXCR5, CD39, CD127, CCR7, CD25, CD317, CD27, CD19, CD20, CD59, CD97, CD14, CD55, cPass SARS-CoV-2 neutralizing antibody test and nucleocapsid (NP) SARS-CoV-2 IgG antibody test. A key feature of this panel is that it distinguishes between naïve and memory B and T cells. The companies expect to Excellerate the Long COVID Panel over time by adding key new biomarkers that become validated in the literature, as well by removing biomarkers that prove inconsequential.

“Our early work with Tollovid in Long COVID seems to support the hypothesis that 3CL protease inhibition can have an impact on neutralizing antibody levels, however much more research is needed to understand and quantify this impact,” said Gerald Commissiong, President & CEO of Todos Medical. “We have seen a very high percentage of participants in our case study series discover upon initial screening that they are not producing neutralizing antibodies to SARS-CoV-2, even though they have been vaccinated and infected with the virus. We are also finding that some participants in our case study series produce neutralizing antibodies after extended time on Tollovid with those gains holding as the dose is reduced, whereas some participants do not produce neutralizing antibodies despite Tollovid having an impact on their symptoms while taking the supplement. This tells us that there is something more significant going on with the integrity of their immune system of those that do not produce neutralizing antibodies that requires further investigation. Amerimmune’s testing platform’s ability to measure the immune system’s integrity is profound and has already established itself as a reflex test for Evusheld eligibility; if the Amerimmune test shows a patient to be immune incompetent, then they become eligible for Evusheld prescription. We believe that 3CL protease inhibition and viral neutralization will be required to eliminate viral persistence in Long COVID, as viral persistence is emerging as a core feature of virus-induced Long COVID.”

For more information on the Amerimmune Long COVID Panel please visit:

https://www.amerimmunediagnostics.com/labeval

To purchase Tollovid please visit Amazon or www.MyTollovid.com.

About Tollovid(R) and Tollovid Daily(TM)

Tollovid and Tollovid Daily are oral dietary supplement products made from natural ingredients that help support and maintain healthy immune function and also have potent 3CL protease inhibition properties based upon in vitro functional assays that show strong inhibition of 3CL protease activity. Tollovid’s 3CL protease IC50 binding affinity is at least ten times (10x) as strong as Ivermectin’s published 3CL protease IC50 binding affinity. Tollovid Daily’s 3CL protease IC50 binding affinity is at least two and a half times (2.5x) as Ivermectin. Tollovid and Tollovid Daily bind to the active site (receptor binding domain) of the 3CL protease. Tollovid has a 5-day dosing regimen, with 4 doses of 3 pills taken each day that provides maximum immune support. Tollovid Daily is a daily immune support product with a dosing regimen of twice daily. Preliminary data from an ongoing IRB-waiver study of customers who used the products to assist with their COVID and Long COVID was recently announced.

To purchase Tollovid please visit Amazon or www.MyTollovid.com.

About Tollovir(R)

Tollovir(R) is an oral 3CL protease inhibitor and anti-cytokine therapeutic candidate for the intervention of the Nidovirus group of viruses that includes coronaviruses such as SARS-CoV-2, COVID-19, SARS-CoV-1, MERS and 229E. Tollovir is made from all natural ingredients that are qualified to ensure strong inhibition of the 3CL protease in vitro, as well as strong anti-cytokine activity. Tollovir has successfully completed a Phase 2 clinical trial in Israel for the treatment of patients hospitalized with COVID-19. Tollovir will be developed for the treatment of hospitalized COVID-19 (severe and critical), moderate COVID-19, long-haul COVID and potentially pediatric COVID-19. Todos has licensed rights for Tollovir to T-Cell Protect Hellas S.A. for the Greek market.

About Todos Medical Ltd.

Founded in Rehovot, Israel with offices in New York City, Todos Medical Ltd. (OTCQB: TOMDF) engineers life-saving diagnostic solutions for the early detection of a variety of cancers. The Company’s state-of-the-art and patented Todos Biochemical Infrared Analyses (TBIA) is a proprietary cancer-screening technology using peripheral blood analysis that examines cancer’s influence on the immune system, looking for biochemical changes in blood mononuclear cells and plasma. Todos’ two internally developed cancer-screening tests, TMB-1 and TMB-2 have received a CE mark in Europe. Todos recently acquired U.S.-based medical diagnostics company Provista Diagnostics, Inc. to gain rights to its Alpharetta, Georgia-based CLIA/CAP certified lab currently performing PCR COVID testing and Provista’s proprietary commercial-stage Videssa(R) breast cancer blood test.

Todos is also developing blood tests for the early detection of neurodegenerative disorders, such as Alzheimer’s disease. The Lymphocyte Proliferation Test (LymPro Test(TM)) is a diagnostic blood test that determines the ability of peripheral blood lymphocytes (PBLs) and monocytes to withstand an exogenous mitogenic stimulation that induces them to enter the cell cycle. It is believed that certain diseases, most notably Alzheimer’s disease, are the result of compromised cellular machinery that leads to aberrant cell cycle re-entry by neurons, which then leads to apoptosis. LymPro is unique in the use of peripheral blood lymphocytes as a surrogate for neuronal cell function, suggesting a common relationship between PBLs and neurons in the brain.

Todos formed the Israeli-based majority-owned joint venture 3CL Pharma, Ltd with NLC Pharma in March of 2022 to consolidate all of the intellectual property pursuing the development of diagnostic tests targeting the 3CL protease, as well as 3CL protease inhibitor botanical and pharmaceutical products that target a fundamental reproductive mechanism of coronaviruses. 3CL Pharma, through Todos’ brand, has commercialized the 3CL protease inhibitor immune support dietary supplement Tollovid(R) in the United States, is developing the dual mechanism 3CL protease inhibitor & anti-cytokine therapeutic drug candidate Tollovir(R), while also developing the 3CL protease inhibitor diagnostic TolloTest(TM).

For more information, please visit https://www.todosmedical.com/.

About Amerimmune Diagnostics LLC

Founded in 2010, Amerimmune Diagnostics focuses on immunological testing as a solution to the unmet need and timely diagnosis of immune disorders. Amerimmune combines immunophenotyping flow cytometry testing, expert interpretation and recommendations. Amerimmune testing empowers the private practitioner to optimally manage their patient population.

For more information, please visit amerimmunediagnostics.com.

Forward-looking Statements

Certain statements contained in this press release may constitute forward-looking statements. For example, forward-looking statements are used when discussing our expected clinical development programs and clinical trials. These forward-looking statements are based only on current expectations of management, and are subject to significant risks and uncertainties that could cause real results to differ materially from those described in the forward-looking statements, including the risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval or patent protection for product candidates; competition from other biotechnology companies; and our ability to obtain additional funding required to conduct our research, development and commercialization activities. In addition, the following factors, among others, could cause real results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; delays or obstacles in launching our clinical trials; changes in legislation; inability to timely develop and introduce new technologies, products and applications; lack of validation of our technology as we progress further and lack of acceptance of our methods by the scientific community; inability to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties that may develop with our process; greater cost of final product than anticipated; loss of market share and pressure on pricing resulting from the competition; and laboratory results that do not translate to equally good results in real settings, all of which could cause the real results or performance to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, Todos Medical does not undertake any obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertainties affecting Todos Medical, please refer to its reports filed from time to time with the U.S. Securities and Exchange Commission.

Todos Corporate Contact:

Daniel Hirsch

CFO

Todos Medical

917-983-4229 x 104

Dan.h@todosmedical.com

View the original release on www.newmediawire.com

Wed, 27 Jul 2022 23:46:00 -0500 en text/html https://apnews.com/press-release/newmediawire/covid-technology-health-middle-east-f0b14c8491ba20108853caa04947fbd5
Killexams : LOCAL MEDICAL CENTERS' NEWS

BOND CLINIC

Shailesh Rajguru

Shailesh Rajguru, DO, FACN, was elected the 2022-2025 chairman of the American Osteopathic Board of Neurology and Psychiatry on April 5 by the board members comprised of neurology and psychiatry physicians across the country. Rajguru has been involved with the Bureau of Osteopathic certified since 2016 and has served on different committees such as Standards Review Committee, Certification Compliance Review Committee and the Conjoint Certification Oversight Committee. In addition, he has been a member of the AOBNP since August 2013 and the secretary of the Board since August 2016. As chairman, Rajguru will be responsible for the operational governance of the board as a whole, maintaining healthy relationships with the American Osteopathic Association as well as the American College of Neuropsychiatry. Rajguru began his practice in 1999 after attending the Kansas City University of Medicine and Biosciences in Kansas City, Missouri, for his degree in Osteopathic Medicine and his internship and neurology residency at the University of South Florida in Tampa. Rajguru is board certified in neurology and a fellow of the American College of Neuropsychiatry. He joined Bond Clinic in 2016. Rajguru spearheaded the Nova Southeastern Student Doctor program.

WATSON CLINIC

Jolie Szocki

Board-certified pediatrician Jolie Szocki, M.D., has joined the Watson Clinic team at the Watson Clinic North Pediatrics location, 1430 Lakeland Hills Blvd., Lakeland. Szocki received her medical degree from the University of the West Indies in St. Augustine, Trinidad. She completed her residency in pediatrics at the University of Florida College of Medicine in Gainesville and her fellowship in pediatric hematology and oncology at the University of Florida College of Medicine in Jacksonville. Szocki is board-certified by the American Board of Pediatrics and is a member of the American Association of Pediatrics and the American Society of Pediatric Hematology and Oncology.

The Watson Clinic Foundation Arts in Medicine program offers a Breast Cancer Survivorship Series with the support of local partners including the Polk Museum of Art, Florida Dance Theater and the Garden Club of Lakeland. The series will be offered twice yearly and consists of four classes per series. The first series of four classes begins in September and continues on the first Thursday of each month through December. Classes are free and open to breast cancer survivors throughout the community who are within their first five years of survivorship (as determined by their date of diagnosis). There are a limited number of seats available, and participants must register prior to Aug. 22, for the first series. Submit a registration request at WatsonClinic.com/Survivorship or call 863-603-4718 for more information. The Breast Cancer Survivorship Series is presented by the Watson Clinic Foundation’s Arts in Medicine program through a grant from the Florida Breast Cancer Foundation.

LAKELAND REGIONAL HEALTH

The following medical professionals have joined the Lakeland Regional Health team.

Ajit Brar

Ajit Brar, M.D., is a board-certified family medicine physician with extensive experience in areas such as geriatrics, sport medicine, primary care and urgent care. Brar also cares for obstetric patients and delivers babies. She earned her medical degree at Ross University School of Medicine in Barbados and completed her residency and fellowship at Mercy Health System in Janesville, Wisconsin. Brar is a member of the American Academy of Family Physicians and sees patients at the LRH Highlands office.

Keisha Ellis

Keisha Ellis, M.D., is a board-certified internal medicine physician specializing in endocrinology with emphasis on the management of obesity, diabetes and thyroid disease. As a clinical professor for graduate medical education, she also serves as the associate program director of the LRH Internal Medicine Residency program. Ellis earned her medical degree at Ross University School of Medicine in Barbados and completed her residency in internal medicine at the University of Connecticut in Storrs, Connecticut, and her fellowship in endocrinology at the University of South Carolina in Columbia, South Carolina. Ellis’s research has been published and presented nationwide. She sees patients at LRH’s Morrell Internal Medicine location.

Ashley Vanegas

Ashley Vanegas, PA-C, is a physician assistant specializing in orthopedics. Vanegas is a member of the Air Force Reserve at MacDill Air Force Base in Tampa and manages the Physical test and Standards program for the Air Force Reserve Wing. She has also held additional clinical leadership positions at MacDill. Vanegas earned her Bachelor of Science in Health Science degree, a Master of Business Administration degree and a Master of Science in Health Sciences degree in Health Care Management at Trident University International in Cypress, California. She then completed her Master of Physician Assistant Medicine degree at the University of Tampa.. Vanegas is certified by the National Commission on Certification of Physician Assistants. She cares for patients at the LRH Medical Center.

Danielle Bennett Baldwin

Danielle Bennett Baldwin, APRN, is a board-certified advanced practice registered nurse specializing in family medicine. She has extensive experience in caring for patients in clinic settings, including walk-in clinics and family practice. After completing a Bachelor of Health Science degree and a Bachelor of Science in Nursing degree at the University of Florida in Gainesville, Baldwin earned a Master of Science in Nursing degree at the University of Florida. She cares for patients at the LRH Lake Miriam Campus.

Yamslee Landfair

Yamslee Landfair, MS, APRN, ACNPC-AG, CCRN, is an advanced practice registered nurse specializing in trauma. Landfair has extensive experience in diagnostic and interventional procedures, and care of critically ill patients. Landfair earned her Bachelor of Science in Nursing degree from Lasalle University in Philadelphia. She earned her Master of Science in Nursing degree and completed a post-master’s fellowship in critical care at the University of Pennsylvania in Philadelphia. She cares for trauma patients at LRH Medical Center.

Akaycha Robinson

Akaycha Robinson, APRN, is an advanced practice registered nurse specializing in cardiovascular thoracic surgery. Robinson has extensive experience in the operating room as well as acute care facilities and intensive care. Robinson earned her Bachelor of Arts in Health Science degree from the University of South Florida in Tampa and her Bachelor of Science in Nursing degree at Utica College in St. Petersburg. She earned her Master of Science in Nursing degree at Walden University in Minneapolis. Robinson is a member of the American Heart Association and the Association of Perioperative Nursing, and cares for patients at  LRH Medical Center.

Lakeland Regional Health recently broke ground at its Interstate-4 and Kathleen Road location. Once complete, along with offering primary care and specialty care, the I-4 location will be home to Lakeland Regional Health’s Graduate Medical Education residency program, with nearly 200 residents in the program once it is fully operational. Currently, four residencies have received accreditation through the Accreditation Council for Graduate Medical Education: general surgery, internal medicine, psychiatry and a surgical critical care fellowship. The organization is exploring future residency programs in emergency medicine, family medicine, obstetrics and gynecology and transitional year. Once the I-4 location opens, Lakeland Regional Health will have nearly 20 facilities in Polk and Hillsborough counties.

This article originally appeared on The Ledger: New members of health groups

Mon, 01 Aug 2022 21:05:00 -0500 en-US text/html https://www.yahoo.com/now/local-medical-centers-news-090512623.html
Killexams : Ivy Tech offering a grant-funded Certified Clinical Medical Assistant training course

BLOOMINGTON — Ivy Tech Community College’s Bloomington campus is offering a 12-week Certified Medical Assistant (CCMA) training course at no cost for eligible students that starts Aug. 23. Grant funding with the state’s Next Level Jobs Workforce Ready Grant covers costs for qualified participants. 

The CCMA course is a short-term, non-credit workforce training opportunity that quickly prepares graduates to qualify for local, high-demand jobs in the field. Classes are held in the evenings from 5 p.m. to 8 p.m. on Tuesdays, Wednesdays, and Thursdays from Aug. 23 to Nov. 10, with a one-week break.

For individuals who may not qualify for funding, the cost of the course is $2,599 and includes course materials, instruction, and the certification test to qualify for employment.

For questions or to get registered, contact Ivy Tech Bloomington’s workforce training office at 812-330-6042 or bloomington-workforcetraining@ivytech.edu. For more information about short-term, non-credit training opportunities, visit www.ivytech.edu/bloomington/ccec.

Ivy Tech Community College offers more than 70 career and four-year transfer programs, with courses that start multiple times per year for quicker entry and graduation.

Thu, 28 Jul 2022 02:29:00 -0500 en-US text/html http://www.wbiw.com/2022/07/28/ivy-tech-offering-a-grant-funded-certified-clinical-medical-assistant-training-course/
Killexams : “Buzz on the Street” Show: Todos Medical (OTCQB: TOMDF) Validation Plan for MonkeyPox Test

FinancialBuzz.com’s latest Buzz on the Street Show: Featuring Our Corporate News Recap on “Todos Medical Initiates Validation Plan for PCR-based MonkeyPox Test at CLIA/CAP Clinical Testing Laboratory Provista Diagnostics.”

Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today announced that its CLIA/CAP-certified laboratory Provista Diagnostics has initiated a validation plan for PCR-based MonkeyPox testing. Under the plan, the Company is validating multiple PCR assays for MonkeyPox and will launch the most sensitive for lesion-based and saliva-based demo collections. While lesion-based testing is the current standard of care according to CDC guidelines, saliva-based demo collection is currently undergoing intense research that could open up the potential for testing of asymptomatic or very early-stage patients at high risk of severe disease (such as immunocompromised patients) that could result in earlier diagnosis and early intervention with therapeutic drugs such as Tecovirimat (TPOXX). TPOXX is an investigational drug candidate, and currently only available under an expanded access Investigational New Drug (EA-IND) protocol. The MonkeyPox tests are being developed as Laboratory Developed Tests (LDTs).

Founded in Rehovot, Israel with offices in New York City, Todos Medical Ltd. (OTCQB: TOMDF) engineers life-saving diagnostic solutions for the early detection of a variety of cancers. The Company’s state-of-the-art and patented Todos Biochemical Infrared Analyses (TBIA) is a proprietary cancer-screening technology using peripheral blood analysis that examines cancer’s influence on the immune system, looking for biochemical changes in blood mononuclear cells and plasma. Todos’ two internally developed cancer-screening tests, TMB-1 and TMB-2 have received a CE mark in Europe.

For more information, please visit: Todos Medical Ltd.

About Buzz on the Street: One of FinancialBuzz.com’s latest corporate and financial news shows, covering the latest trending stock market news. Buzz on the Street looks to become a leader in corporate video news dissemination. Buzz on the Street is 100% original content, brought to you by Financial Buzz Media.

Sponsored Content Release. Click for Full Disclosure

Wed, 03 Aug 2022 08:09:00 -0500 text/html https://www.financialbuzz.com/buzz-on-the-street-show-todos-medical-otcqb-tomdf-validation-plan-for-monkeypox-test/
NCMA-CMA exam dump and training guide direct download
Training Exams List